Marga B Rominger1, Carolin Steinmetz2, Ronny Westerman3, Annette Ramaswamy4, Ute-Susann Albert5. 1. Department of Radiology, University Hospital Zürich, Switzerland. 2. Department of Pediatric Psychiatry, University Hospital Würzburg, Germany. 3. Competence Center for Mortality Follow-up, German National Cohort Study, University Hospital of Philipp University Marburg, Germany. 4. Department of Pathology, University Hospital of Philipp University Marburg, Germany. 5. Department of Gynecology and Obstetrics, Krankenhaus Nordwest, Frankfurt/M., Germany.
Abstract
INTRODUCTION: In this study we evaluated mammographic, histological and immunohistochemical findings for microcalcification-associated breast cancer with regards to breast-conserving therapy, recurrence and survival rate. PATIENTS AND METHODS: We retrospectively analyzed 99 consecutive, non-palpable and microcalcification-associated breast cancers (94 women) that were treated surgically between January 2002 and December 2003 at a national academic breast cancer center. Calcifications were classified according to the Breast Imaging Reporting and Data System (BI-RADS). Descriptors, surgical outcome and histological findings were assessed. Recurrences and survival rates were evaluated based on medical records, standardized patient questionnaires and/or contacting the physician. RESULTS: 42 of the 99 lesions (42.4%) were invasive carcinomas, 57 (57.6%) were pure ductal carcinoma in situ (DCIS). 6 out of 99 (6.1%) lesions were triple negative, and 29 (29.3%) were HER2/neu positive. Successful first excision rate was 76/99 lesions (76.8%). Breast conservation was achieved in 73.7% (73/99). 10 women showed local recurrences without negatively impacting survival. The recurrences included round/punctate, amorphous, fine pleomorphic, and fine linear or fine-linear branching descriptors. The breast cancer-specific long-term survival rate was 91/94 (96.8%) for a mean follow-up of 81.4 months. The 3 patients who died due to breast carcinoma showed fine pleomorphic calcifications, and had nodal-positive invasive carcinoma at diagnosis. CONCLUSION: Microcalcification-associated breast cancers are frequently treated with breast-conserving therapy. Continuous clinical and mammographic follow-up is recommended for all descriptors.
INTRODUCTION: In this study we evaluated mammographic, histological and immunohistochemical findings for microcalcification-associated breast cancer with regards to breast-conserving therapy, recurrence and survival rate. PATIENTS AND METHODS: We retrospectively analyzed 99 consecutive, non-palpable and microcalcification-associated breast cancers (94 women) that were treated surgically between January 2002 and December 2003 at a national academic breast cancer center. Calcifications were classified according to the Breast Imaging Reporting and Data System (BI-RADS). Descriptors, surgical outcome and histological findings were assessed. Recurrences and survival rates were evaluated based on medical records, standardized patient questionnaires and/or contacting the physician. RESULTS: 42 of the 99 lesions (42.4%) were invasive carcinomas, 57 (57.6%) were pure ductal carcinoma in situ (DCIS). 6 out of 99 (6.1%) lesions were triple negative, and 29 (29.3%) were HER2/neu positive. Successful first excision rate was 76/99 lesions (76.8%). Breast conservation was achieved in 73.7% (73/99). 10 women showed local recurrences without negatively impacting survival. The recurrences included round/punctate, amorphous, fine pleomorphic, and fine linear or fine-linear branching descriptors. The breast cancer-specific long-term survival rate was 91/94 (96.8%) for a mean follow-up of 81.4 months. The 3 patients who died due to breast carcinoma showed fine pleomorphic calcifications, and had nodal-positive invasive carcinoma at diagnosis. CONCLUSION: Microcalcification-associated breast cancers are frequently treated with breast-conserving therapy. Continuous clinical and mammographic follow-up is recommended for all descriptors.
Entities:
Keywords:
Breast cancer; Imaging; Prognostic value; Recurrence; Survival
Authors: M F Press; L Bernstein; P A Thomas; L F Meisner; J Y Zhou; Y Ma; G Hung; R A Robinson; C Harris; A El-Naggar; D J Slamon; R N Phillips; J S Ross; S R Wolman; K J Flom Journal: J Clin Oncol Date: 1997-08 Impact factor: 44.544
Authors: D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich Journal: Science Date: 1989-05-12 Impact factor: 47.728
Authors: Emil D Kurniawan; Matthew H Wong; Imogen Windle; Allison Rose; Arlene Mou; Malcolm Buchanan; John P Collins; Julie A Miller; Russell L Gruen; G Bruce Mann Journal: Ann Surg Oncol Date: 2008-07-10 Impact factor: 5.344
Authors: J Thomas; A Evans; J Macartney; S E Pinder; A Hanby; I Ellis; O Kearins; T Roberts; K Clements; G Lawrence; H Bishop Journal: Br J Cancer Date: 2010-01-05 Impact factor: 7.640